Since transforming growth factor β (TGF-β) is presumed to play a role in lung fibrosis, we evaluated the effect of suramin (Sur), a substance with an anti-TGF-β effect, in vivo on bleomycin (Bleo)-induced pulmonary injury in mice and in vitro on human lung fibroblasts. Four groups of C57BL/6 mice each received one of four treatments: (1) intratracheal (IT) instillation of B leo and intraperitoneal (IP) injections of Sur, every other day, starting one day before IT instillation of Bleo (Bleo-Sur); (2) IT Bleo and IP injections of saline (Bleo-Sal); (3) IT saline and IP Sur (Sal-Sur); and (4) IT and IP saline (Sal-Sal). Animals were sacrificed 14 days after IT treatment. Lung injury was evaluated by analysis of bronchoalveolar lavage (BAL) fluid, histologically by the semiquantitative morphological index, and biochemically by analysis of lung hydroxyproline content. In vitro, Sur did not affect TGF-β induced increase of α1 (I) collagen mRNA in human lung fibroblasts. In viva treatment of mice with Sur did not affect Bleo-induced lung injury. These results indicate that despite its potential anti TGF-β and lymphocytotoxic effects, Sur is not a therapeutic candidate drug for rescue of lung fibrosis. (C) 2000 Elsevier Science Inc.
- Interstitial lung disease
ASJC Scopus subject areas